Bide Pharmatech Co., Ltd. (SHA:688073)
China · Delayed Price · Currency is CNY 49.51
-0.47 (-0.94%)
At close: Jun 2, 2026
Bide Pharmatech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,351 | 1,324 | 1,102 | 1,092 | 833.8 | 606.05 |
Other Revenue | 0 | 0 | 0.01 | 0.03 | 0.03 | 0.17 |
| 1,351 | 1,324 | 1,102 | 1,092 | 833.83 | 606.22 | |
Revenue Growth (YoY) | 18.93% | 20.13% | 0.93% | 30.95% | 37.55% | 54.86% |
Cost of Revenue | 773.61 | 773.33 | 680.35 | 673.38 | 471.29 | 315.89 |
Gross Profit | 577.11 | 550.48 | 421.66 | 418.48 | 362.54 | 290.33 |
Selling, General & Admin | 298.14 | 293.96 | 244.87 | 250.12 | 167.26 | 145.16 |
Research & Development | 59.29 | 59.44 | 55.62 | 59.72 | 43.46 | 32.1 |
Other Operating Expenses | 1.04 | 5.27 | 6.43 | 5.01 | 3.96 | 2.42 |
Operating Expenses | 362.6 | 362.81 | 308.68 | 319.18 | 218.2 | 182.75 |
Operating Income | 214.51 | 187.67 | 112.99 | 99.3 | 144.34 | 107.58 |
Interest Expense | -5.8 | -5.8 | -3.32 | -2.53 | -2.16 | -0.92 |
Interest & Investment Income | 18.65 | 19.34 | 23.74 | 31.74 | 8.86 | 3.9 |
Currency Exchange Gain (Loss) | -17.94 | -17.94 | 4.99 | 5.93 | 12.55 | -6.67 |
Other Non Operating Income (Expenses) | -14.14 | -2.11 | -4.12 | -2.5 | -2.23 | -1.08 |
EBT Excluding Unusual Items | 195.27 | 181.17 | 134.28 | 131.95 | 161.35 | 102.8 |
Gain (Loss) on Sale of Investments | -0.47 | 0.67 | 3.15 | -12.63 | -0.46 | - |
Gain (Loss) on Sale of Assets | 8.54 | 3.9 | 1.15 | 0.44 | - | 7.92 |
Asset Writedown | -0.69 | -1.11 | -0.03 | -0 | -0 | -0.04 |
Other Unusual Items | 10.81 | 10.81 | 9.46 | 6.25 | 10.88 | 3.87 |
Pretax Income | 213.46 | 195.43 | 148.02 | 126 | 171.77 | 114.56 |
Income Tax Expense | 45.58 | 43.69 | 30.59 | 17.55 | 25.8 | 16.99 |
Earnings From Continuing Operations | 167.88 | 151.74 | 117.43 | 108.45 | 145.97 | 97.57 |
Minority Interest in Earnings | - | - | - | 1.13 | - | - |
Net Income | 167.88 | 151.74 | 117.43 | 109.57 | 145.97 | 97.57 |
Net Income to Common | 167.88 | 151.74 | 117.43 | 109.57 | 145.97 | 97.57 |
Net Income Growth | 37.55% | 29.22% | 7.17% | -24.94% | 49.60% | 65.37% |
Shares Outstanding (Basic) | 86 | 87 | 89 | 91 | 74 | 67 |
Shares Outstanding (Diluted) | 87 | 88 | 89 | 91 | 74 | 67 |
Shares Change (YoY) | -2.50% | -1.40% | -1.76% | 22.83% | 10.09% | 8.03% |
EPS (Basic) | 1.96 | 1.75 | 1.32 | 1.21 | 1.98 | 1.46 |
EPS (Diluted) | 1.93 | 1.73 | 1.32 | 1.21 | 1.98 | 1.46 |
EPS Growth | 41.08% | 31.06% | 9.09% | -38.89% | 35.89% | 53.38% |
Free Cash Flow | 35.52 | 4.04 | 69.97 | -118.47 | -8.54 | -94.09 |
Free Cash Flow Per Share | 0.41 | 0.05 | 0.79 | -1.31 | -0.12 | -1.41 |
Dividend Per Share | 1.160 | 1.160 | 0.900 | 0.900 | 1.100 | - |
Dividend Growth | 28.89% | 28.89% | - | -18.18% | - | - |
Gross Margin | 42.73% | 41.58% | 38.26% | 38.33% | 43.48% | 47.89% |
Operating Margin | 15.88% | 14.18% | 10.25% | 9.09% | 17.31% | 17.75% |
Profit Margin | 12.43% | 11.46% | 10.66% | 10.04% | 17.51% | 16.10% |
Free Cash Flow Margin | 2.63% | 0.30% | 6.35% | -10.85% | -1.02% | -15.52% |
EBITDA | 229.49 | 201.88 | 124.12 | 108.85 | 150.15 | 111.51 |
EBITDA Margin | 16.99% | 15.25% | 11.26% | 9.97% | 18.01% | 18.39% |
D&A For EBITDA | 14.98 | 14.21 | 11.13 | 9.55 | 5.81 | 3.93 |
EBIT | 214.51 | 187.67 | 112.99 | 99.3 | 144.34 | 107.58 |
EBIT Margin | 15.88% | 14.18% | 10.25% | 9.09% | 17.31% | 17.75% |
Effective Tax Rate | 21.35% | 22.36% | 20.67% | 13.93% | 15.02% | 14.83% |
Revenue as Reported | 1,324 | 1,324 | 1,102 | 1,092 | 833.83 | 606.22 |
Advertising Expenses | - | 8.18 | 9.59 | 7.77 | 5.65 | 5.87 |